Database for patients treated with metabolic radiotherapy
Official title: Establishment of a Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
Run by Institut du Cancer de Montpellier - Val d'Aurelle · NCT04104529 · Data updated 2026-11-12
This study is creating a database to collect information and samples from patients with thyroid, prostate, and neuroendocrine tumors who are receiving targeted radiation therapy, to see how it works and improve treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 350 (estimated) |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle Academic / other |
| Drugs / interventions | radiation |
| Locations | 4 sites (Bordeaux, Aquitaine and 3 other locations) |
| Status | Recruiting |
| Started | October 28, 2019 |
| Main results expected | October 2029 |
| Study ends | October 2029 |
| Registry record updated | September 15, 2026 |
| Trial ID | NCT04104529 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older who are being treated with metabolic radiotherapy for thyroid cancer, prostate cancer, or neuroendocrine tumors.
✕Probably not a fit
Patients who are not affiliated with a social security scheme or those in emergency situations may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to develop a clinico-biological database that collects clinical data and biological materials from patients undergoing targeted radionuclide therapy (TRT) for thyroid cancer, prostate cancer, and neuroendocrine tumors. The study will utilize various radionuclides to deliver radiation specifically to tumor cells, enhancing treatment effectiveness. By integrating clinical and biological data, the research seeks to improve understanding of the radiobiological effects of TRT and optimize treatment strategies. The database will also facilitate collaboration among researchers to advance medical knowledge and patient care.
Why it matters
Potential benefit: If successful, this initiative could lead to improved treatment outcomes for patients with thyroid cancer, prostate cancer, and neuroendocrine tumors.
How similar studies have gone: Other studies utilizing targeted radionuclide therapy have shown promising results, indicating potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ at 18 years old, * Patient treated in the Nuclear Medicine Department for the treatment by metabolic radiotherapy, * Patient treated as part of his treatment for: * thyroid cancer, * a neuroendocrine tumor or any SSTR positive tumours (like meningiomas) receiving PRRT * prostate cancer. * Patient having accepted the complementary blood sample, * Patient having given his informed, written and express consent. Exclusion Criteria: * Patient not affiliated to a social security scheme, * Subject under tutelage, curatorship or safeguard of justice, * Patient in an emergency situation * Patient whose regular monitoring is a priori impossible for psychological, family, social or geographical reasons, * Pregnant and / or breastfeeding woman
Where it's running
-
Hopital Haut Lévêque
Bordeaux, Aquitaine, France Recruiting -
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, France Recruiting -
Institut Universitaire du Cancer de Toulouse
Toulouse, France Recruiting -
Hôpital LaTimone
Marseille, Bouches Du Rhône, France Not yet recruiting
Study contacts
- Study coordinator: Aurore MOUSSION
- Email: DRCI-icm105@icm.unicancer.fr
- Phone: 0467613102
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
A resource for collecting cancer data and biospecimens
This study is creating a resource to collect health information and samples from cancer patients and healthy individuals to help improve cancer prevention and treatment strategies.
-
Meaning-Centered Therapy for Latinos for adults with advanced cancer
This study tests whether Meaning-Centered Psychotherapy for Latinos (MCP-L) can reduce anxiety and depression and improve quality of life compared with CBT in Spanish-speaking adults with advanced cancer.
-
Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors
This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.
-
Using a new molecular probe for early diagnosis of tumors
This study is testing a new imaging tool to see if it can help doctors find different types of tumors earlier in patients aged 18 to 75 who already have confirmed tumor lesions.
-
ImmunoPET imaging for solid tumors targeting Trop2
This study is testing a new imaging method to see if it can help diagnose solid tumors like bladder and prostate cancer better than current methods.
-
Using brodalumab to treat immune-related side effects from cancer therapy
This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.